Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 29 (14) 2621-2630
Year:
2023
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
12
Parents:
3714  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA189858, UG1CA189960, UG1CA233163, UG1CA233180, UG1 CA233320, UG1CA233290, UG1CA233337, UG1CA233339; UG1CA233234, U10CA180863, CCS Grant # 707213(CCTG); U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888, UG1CA233163(SWOG), R01CA205406, R33CA160344, P30 CA008748, P30 CA015083  
Corr. Author:
 
Authors:
                                                 
Networks:
CA136, HEARTLAND, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-MD017, LAPS-MO011, LAPS-NY016, LAPS-OH007, OH027, OR013   
Study
Alliance-A151939
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80702
Phases:
N/A, 3
Keywords:
colon adenocarcinoma, recurrence, survival, 25(OH)D, inflammation, biomarker